Many established, as well as niche or start-up pharmaceutical and biopharmaceutical companies are keen on the prospect of launching products into multiple markets, but often do not have the resources and expertise to do so. Patients, meanwhile, are deprived of access to new life saving drugs, which are simply not available in their territory.